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A goal in cancer therapeutics is to develop targeted
modalities that distinguish malignant from normal
cells. T cells can discriminate diseased cells based on
subtle alterations in peptides displayed in association
with MHC molecules at the cell surface. Recent suc-
cess using the adoptive transfer of tumor-specific T
cells has fueled optimism that this approach may
find a place as a targeted therapy for some human
cancers.
 
The ability to adoptively transfer T cells to treat cancer
and infections has been demonstrated in rodent models, but
the task of translating the principles established in animal
studies into the clinic has not been easy. A notable achieve-
ment in adoptive T cell therapy in humans was its use to
control infections caused by cytomegalovirus (CMV) and
Epstein Barr virus (EBV) in immunocompromised alloge-
neic bone marrow transplant recipients (1–3). This was a
logical beginning for clinical application of T cell therapy
because the pretransplant conditioning and immunosuppres-
sive drugs administered to bone marrow transplant recipi-
ents cause a severe T cell deficiency that correlates with
progressive infection. Moreover, virus-specific CD8
 
 
 
 T
cells, which are the critical effector cells for controlling
these viruses, could be readily isolated and expanded from
the immunocompetent bone marrow donor for adoptive
transfer. In the case of EBV infection in bone marrow
transplant patients, a lymphoproliferative disease (EBV-
LPD) of EBV-infected B cells was the target of therapy.
The malignant B cells in EBV-LPD express a subset of
EBV genes referred to as the latency III program, which
includes the highly immunogenic EBNA-3A, 3B, and 3C
proteins (4, 5). The adoptive transfer of EBV-specific T
cells isolated from the transplant donor and consisting primar-
ily of CD8
 
 
 
 T cells specific for EBNA 3 proteins promoted
regression of established EBV-LPD in transplant recipients
and prevented the development of tumors when given
prophylactically (3, 6).
 
Extending the Role of EBV-specific T Cells for Therapy of
EBV-associated Malignancies.
 
Several malignancies that oc-
cur in immunocompetent individuals also contain the
EBV genome including a subset of Burkitt’s lymphoma,
Hodgkin’s disease, and nasopharyngeal carcinoma. These
malignancies express one or more of the EBNA-1, LMP-1,
and LMP-2 viral proteins, which cooperate in establishing
the malignancy (5). There has been pessimism regarding
whether specific T cell therapy targeting either EBNA-1,
LMP-1, or LMP-2 would be possible since these proteins
are weakly immunogenic and the tumors evade immune
recognition by a variety of mechanisms. In this issue, Bollard
et al. show that the adoptive transfer of EBV-reactive T cells
to patients with Hodgkin’s disease can augment CD8
 
 
 
 T
cell immunity to the weakly immunogenic LMP-2 protein,
and that the infused T cells migrate to tumor sites and pro-
mote tumor regression (7). The authors appropriately urge
caution in interpreting their study, which analyzed only a
small number of patients who also had recent chemotherapy
or radiation. Nevertheless, coupled with the recent success
using adoptive T cell therapy to treat melanoma and leukemia
(8–10) these results justify current efforts to discover anti-
gens expressed by human tumors and improve the method-
ology for isolating tumor-reactive T cells that can survive
and function in vivo after adoptive transfer.
 
Obstacles to Identifying Tumor-associated Antigens for T Cell
Therapy.
 
A key step in the development of T cell therapy
is the discovery of antigens expressed by malignant cells.
Much of the focus has been on identifying antigens recog-
nized by cytolytic CD8
 
 
 
 T cells because this subset is criti-
cal in murine models of T cell immunotherapy for cancer.
Oncogenic viral proteins, such as EBNA-1, LMP-1, and
LMP-2, that are expressed in the malignant Reed Sternberg
cells in 
 
 
 
40% of Hodgkin’s disease patients represent logical
target antigens because they are absent on normal cells and
cooperate in cell transformation. However, targeting these
antigens with adoptive T cell therapy has not been straight-
forward. The CD8
 
 
 
 T cell response to EBV is strongly fo-
cused on lytic cycle EBV proteins and the EBNA 3 anti-
gens, with only weak responses detected to LMP-1 and
LMP-2 (4). EBNA-1 was long considered a poor target for
therapy because it contains a Gly-Ala repeat sequence that
both inhibits proteosomal degradation needed to generate
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most immunogenic peptides and reduces EBNA-1 mRNA
translation (11, 12). However, recent studies show that
EBNA-1–specific CD8
 
 
 
 T cells can be detected in vivo and
inhibit the outgrowth of EBV-transformed cells in vitro,
resurrecting the notion that EBNA-1 might also be a useful
target antigen (13, 14). Thus, although LMP-1 and LMP-2
are considered the most likely targets for effective immuno-
therapy of Hodgkin’s disease, careful analysis of patients that
receive adoptive T cell therapy will be required to deter-
mine the specificity of T cells that promote tumor regres-
sion, particularly if polyclonal populations of EBV-reactive
T cells are administered.
Antigens expressed by human cancers that do not de-
velop as a consequence of oncogenic viruses have also been
identified as potential targets for T cell therapy, but many
have conceptual or practical limitations. In allogeneic stem
cell transplantation, T cells specific for minor histocompati-
bility antigens, which are peptides that differ between donor
and recipient due to polymorphism in the genome, provide
a potent graft versus leukemia effect (15). However, T cells
specific for some minor histocompatibility antigens are also
responsible for graft versus host disease, and a means of reli-
ably segregating the beneficial graft versus leukemia effect
from graft versus host disease has not yet been established.
Autologous T cells could potentially recognize tumor
antigens that arise from mutated proteins or nonmutated
self-proteins in human malignancies. Mutated proteins are
conceptually attractive targets because they are often in-
volved in cell transformation and could provide antigens to
which the host is not tolerant. However, many mutations
are specific for a single patient’s tumor or involve point
mutations or fusion proteins with limited immunogenicity,
and identifying T cells reactive with these determinants has
proven difficult in most patients.
Nonmutated self-proteins represent the largest group of
tumor-associated antigens and include proteins that are ex-
pressed in a tissue-specific fashion such as the melanosome
proteins in malignant melanoma, proteins that are overex-
pressed as a consequence of cellular transformation such as
Her-2/neu in breast cancer, and proteins that are atypically
expressed, such as the cancer-testes antigens, in many tu-
mors (16). It was perceived that tolerance mechanisms
would limit the repertoire or responsiveness of T cells spe-
cific for self-proteins. However, such T cells are increas-
ingly being found in the blood or locally infiltrating tumors
in cancer patients, providing evidence that the immune
system detects the tumor even if the response is quantita-
tively or qualitatively insufficient to promote tumor regres-
sion. A critical issue is to identify which nonmutated self-
antigens are best suited for targeted T cell therapy. Several
factors related to antigen expression should be considered
including expression on normal cells, homogeneity of ex-
pression on tumor cells and tumor stem cells, and the pro-
pensity for tumors to escape by loss of antigen expression.
 
The Isolation and Expansion of T Cells for Immunotherapy.
 
The in vitro expansion of T cells reactive with antigens ex-
pressed on tumor cells could overcome quantitative and
qualitative defects but can represent a daunting obstacle be-
cause of the poor stimulatory capacity or availability of tu-
mor cells. In the case of EBV-associated malignancies such
as Hodgkin’s disease, autologous B cells transformed in
vitro with EBV (EBV-LCL) were used as APCs. EBV-LCL
express all of the EBV-latent proteins in Hodgkin’s disease
and high levels of MHC molecules and ligands for T cell
costimulatory receptors. However, EBV-LCL predomi-
nantly expand CD8
 
 
 
 T cells specific for the immunodomi-
nant EBNA-3 proteins that are not expressed in Hodgkin’s
disease. Indeed, in the study by Bollard et al. LMP-2–reac-
tive T cells represented only a small minority of the infused
T cell population (7), and one might speculate that greater
antitumor activity may be achieved if methods to selec-
tively enrich LMP-1–specific T cells were employed and
greater numbers of tumor-reactive T cells were infused.
The molecular characterization of tumor-associated anti-
gens has aided the development of methods for the selec-
tive isolation and expansion of tumor-reactive T cells in
vitro. Stimulation of T cells with autologous or artificial
APCs pulsed with antigenic peptides or transfected with
genes that encode tumor or viral antigens has been used to
enrich polyclonal T cells for a desired specificity (17, 18).
Peptide–MHC tetramers and bispecific antibodies have also
been developed for isolating specific T cells by flow cytom-
etry or immunomagnetic selection (19, 20). It is possible to
confer specificity for tumors by introducing the genes that
encode the 
 
 
 
 and 
 
 
 
 chains of a T cell receptor of known
specificity and MHC restriction into T cells (21), or by in-
troducing engineered chimeric immunoreceptors that link
a tumor-targeting antibody domain to the TCR 
 
 
 
 chain
(22). These latter approaches diminish the arduous task of
isolating tumor-reactive T cells from patients but have yet
to be proven clinically effective and may impose additional
risk due to gene insertion. Once tumor-reactive T cells are
isolated, techniques have been established to efficiently
propagate these T cells in vitro using IL-2 and antibodies
that activate signaling through CD3 and costimulatory
molecules. Thus, the ability to generate T cells for immu-
notherapy is progressively improving and will facilitate ad-
ditional trials of targeted immunotherapy for human malig-
nancy with autologous tumor-reactive T cells or T cell
clones (Fig. 1).
 
Selecting the “Right” T Cells for Adoptive Therapy.
 
The
adoptive transfer of T cells that recognize antigens ex-
pressed by malignant cells should in principle allow for pre-
cise control of the function and magnitude of T cell im-
munity and should correct quantitative or qualitative
deficiencies in the host response. However, in many clini-
cal trials cultured CD8
 
 
 
 T cells have engrafted poorly per-
haps due to a lack of CD4
 
 
 
 T cells needed to provide
helper functions or to a long duration of culture in exces-
sive concentrations of IL-2, which drives T cells to termi-
nal differentiation and conditions them for death with sub-
sequent activation or cytokine withdrawal. CD4
 
 
 
 T cells
are important for optimal CD8
 
 
 
 T cell immunity, and
adoptive transfer studies in humans in which well-charac-
terized populations of CD4
 
 
 
 T cells, alone or in combina-
tion with CD8
 
 
 
 T cells, are administered are necessary to 
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define their potential role in improving the efficacy of
adoptive therapy.
Antigen-specific T cells represent heterogeneous popula-
tions of differentiated cells that include effector, effector–
memory, and central–memory subsets that can be distin-
guished by functional properties and the differential expres-
sion of homing receptors and costimulatory molecules (23).
The transition between these subsets is not completely un-
derstood and has not been easy to orchestrate in vitro. The
procedures for isolating and expanding T cells in culture
generate effector cells, which might have optimal antitu-
mor activity but exhibit a short survival time in vivo analo-
gous to effector cells generated de novo in a primary im-
mune response. In murine models, the transfer of CD8
 
 
 
effector cells that express the IL-7R
 
 
 
 chain, which could
provide both survival and proliferative signals, led to the es-
tablishment of persistent T cell memory (24), suggesting
that subsets of effector cells might be selected with an im-
proved ability to persist in vivo.
Careful immunologic monitoring of patients treated
with adoptive immunotherapy is proving essential to pro-
vide insight into the qualities of T cells that predict long-
term persistence in vivo after adoptive transfer. Flow cy-
tometry with MHC tetramers or molecular monitoring to 
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detect T cell receptor genes or an introduced marker gene
has been used to track the fate of transferred T cells in vivo.
These monitoring techniques are easily applied for tracking
transferred T cells in the blood and can also be employed to
examine migration to lymph nodes or tumor sites. The use
of MHC tetramers for detecting transferred cells also allows
the isolation of viable cells from the blood or tumor sites
for functional analysis.
Monitoring of patients that receive adoptive immuno-
therapy has revealed the importance of costimulatory
molecule expression in determining cell survival in vivo.
Adoptively transferred melanoma-reactive T cells that per-
sisted long term exhibited a CD28
 
 
 
 CD27
 
 
 
 phenotype,
suggesting these costimulatory molecules were reacquired
on surviving cells or that a subset of CD28
 
 
 
 CD27
 
 
 
 cells in
the infused population selectively survived and expanded in
vivo (25). In HIV-infected patients, CD27
 
 
 
 HIV-specific
T cells rapidly disappeared after adoptive transfer, whereas
CD27
 
 
 
 cells derived from the same clone persisted at high
frequency (26). Future studies are likely to use more so-
phisticated methods for monitoring, including gene expres-
sion arrays, and may define properties of antigen-specific T
cells that correlate with improved persistence and antitu-
mor efficacy.
 
Modifying the Host Environment to Promote the Efficacy of T
Cell Therapy.
 
The environment into which T cells are
adoptively transferred can also have a significant effect on
cell survival and therapeutic efficacy. Transferred CD8
 
 
 
CMV-specific T cell clones survived in vivo as functional
memory cells only in patients with antigen-specific CD4
 
 
 
 T
cell responses, suggesting an important role for CD4
 
 
 
 T
cells in improving cell persistence (1). The administration of
low dose IL-2, which is produced by CD4
 
 
 
 T cells and
promotes T cell proliferation and survival in vitro, im-
proved the survival of transferred melanoma-reactive T cells
in vivo (9). Other cytokines that share the common 
 
 
 
 chain
receptor and regulate lymphocyte growth and survival, such
as IL-7, IL-15, and IL-21, are also being investigated for im-
proving the efficacy of adoptively transferred T cells.
Studies in murine models suggest that lymphodepletion
induced by total body irradiation or other modalities might
be exploited to improve the antitumor efficacy of adop-
tively transferred T cells (27). The lymphopenic environ-
ment may be favorable for several reasons including the
availability of space for transferred T cells in the lymphoid
compartment, less competition for homeostatic cytokines,
such as IL-7 and IL-15, and the elimination of CD4
 
 
 
CD25
 
 
 
 regulatory T cells. This approach has been exam-
ined recently in human trials of adoptive T cell therapy for
melanoma. Patients were first treated with lymphodeplet-
ing chemotherapy followed by the administration of tu-
mor-reactive T cells expanded in vitro from tumor infil-
trates and systemic high-dose IL-2. Transferred T cells
underwent dramatic in vivo expansion in a subset of pa-
tients, infiltrated into tumor sites, and promoted tumor re-
gression (8). In some patients, transferred T cells comprised
a large fraction (up to 70%) of the total peripheral blood
lymphocytes for several months after T cell infusion. These
results although encouraging were not without complica-
tions as many responding patients exhibited autoimmune
destruction of normal melanocytes (8). Additional studies
are needed to determine if lower doses of IL-2 or other cy-
tokines would be effective in promoting T cell persistence
after transfer into a lymphopenic environment and to de-
termine if autoimmunity can be controlled without com-
promising antitumor activity.
 
Overcoming Tumor Immune Evasion.
 
Although progress
has been made in tumor-specific T cell therapy, malignan-
cies are formidable adversaries, and the majority of treated
patients still fail to completely respond to therapy or
progress after an initial response. This likely reflects strate-
gies that tumors utilize to overcome immune recognition,
which may include defects in the processing or presenta-
tion of tumor antigens, production of factors that disable
tumor-reactive T cells, and encasement in a stromal envi-
ronment that is inhospitable to immune attack (28, 29).
This illustrates the importance of monitoring not only the
transferred T cells but also the characteristics of tumors that
respond or fail to respond to therapy to derive insights into
the critical immune evasion mechanisms that must be over-
come to improve efficacy. T cells can be readily modified
by gene insertion to introduce molecules that promote T
cell signaling or homing to tumor sites or interfere with
signaling by inhibitory molecules (30). Thus, tools are
available to enhance the efficacy of T cell therapy, which
based on progress in immunology and tumor cell biology
appears to be gradually assuming a place in the armamen-
tarium of targeted cancer therapies.
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